Stryker Co. (NYSE:SYK) Holdings Lifted by Venturi Wealth Management LLC

Venturi Wealth Management LLC boosted its position in shares of Stryker Co. (NYSE:SYK) by 2.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,789 shares of the medical technology company’s stock after buying an additional 42 shares during the quarter. Venturi Wealth Management LLC’s holdings in Stryker were worth $644,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of SYK. Parnassus Investments LLC bought a new position in Stryker during the third quarter valued at about $762,798,000. International Assets Investment Management LLC boosted its stake in Stryker by 66,967.5% during the third quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock valued at $308,433,000 after buying an additional 852,496 shares in the last quarter. RTW Investments LP bought a new position in Stryker during the third quarter valued at about $143,392,000. State Street Corp boosted its stake in Stryker by 2.2% during the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock valued at $5,279,788,000 after buying an additional 316,404 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Stryker by 3.0% in the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock valued at $2,639,725,000 after purchasing an additional 215,782 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and issued a $420.00 price target (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Citigroup increased their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $420.68.

Stryker Stock Up 0.7 %

SYK opened at $388.30 on Thursday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The business has a 50-day moving average of $377.69 and a 200-day moving average of $368.08. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market capitalization of $148.17 billion, a PE ratio of 50.04, a price-to-earnings-growth ratio of 2.90 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business posted $3.46 EPS. Equities research analysts forecast that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.